Veterinary medical mycology often differs from the human counterpart by the clinical aspects, the variety of fungi involved, and the antimycotic drugs available. Since the 1980s, there has been a significant increase in the number of humans affected by mycoses, and the spectrum of fungal species defined as pathogenic has broadened due to the increasing immunosuppression in the population. In veterinary mycology, this phenomenon has not been observed or is still insufficiently investigated. Only in the last few years the interest and awareness of the importance of animal mycoses and their treatment have increased. Convincing data present identification of previously human pathogens e.g. Cryptococcus gattii or Sporothrix brasiliensis, in animals. There are also revisions in taxonomy of some groups of fungi. The development of new antifungal drugs with better pharmacological properties, a broader spectrum of activity and fewer adverse effects was largely stimulated by the aforementioned increase of cases of fungal infections and the variety of causative agents. Some of these newly developed antifungal drugs are very expensive and, as is well known, economic considerations have a much greater influence on the decision to treat animals than it is in humans. Unfortunately, it is still often believed that the value of an animal is calculated in relation to the cost of therapy. This article reviews the literature on the treatment of fungal and yeast infections from the veterinary perspective of antifungal therapy. Particular attention was paid to the characteristics of disseminated mould mycoses in dogs, as there are numerous reports in the scientific literature in this field